Meeting
2020 ASCO Virtual Scientific Program
Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab.
Authors
Nazanin Majd
MD Anderson Cancer Center, Houston, TX
Nazanin Majd , Heather Y. Lin , Ying Yuan , Kristin Alfaro-Munoz , Kathy Hunter , Amy B. Heimberger , John Frederick De Groot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02337686
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2559)
DOI
10.1200/JCO.2020.38.15_suppl.2559
Abstract #
2559
Poster Bd #
50
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2024 ASCO Genitourinary Cancers Symposium
Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023).
First Author: Sanjay Khanna
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Expanding immunotherapy options in cholangiocarcinoma: Role of CD27 agonist in combination with PD-L1 and MEK inhibition on antitumor effect and CD8+ T cells.
First Author: Frances Jenkins Bennett